← Back to Search

Angiotensin Receptor Blocker

Losartan for Arthrofibrosis

Phase 4
Waitlist Available
Led By Joshua Rozell, MD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days post-surgery
Awards & highlights
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial

Summary

This trial is testing if Losartan, a blood pressure medication, can help reduce scar tissue and stiffness in patients after knee replacement surgery. It aims to improve movement and reduce the need for additional surgeries. Losartan has been studied for various effects including reducing blood pressure and improving heart function.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days post-surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days post-surgery for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Post-Operative Range of Motion (ROM)
Post-Operative Rate of Manipulation under Anesthesia (MUA)

Side effects data

From 2021 Phase 4 trial • 227 Patients • NCT02188121
43%
Laboratory values outside normal range
23%
Psychiatric Hospitalization
6%
Medical Hospitalization
2%
Elevated creatine kinase level
1%
Muscle pain
1%
Hypotension
1%
Dehydration
1%
Leukemia
1%
Placed on Lithium while on Losartan
100%
80%
60%
40%
20%
0%
Study treatment Arm
Statin and/or Angiotensin Receptor Blocker
Usual Treatment

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Losartan GroupExperimental Treatment1 Intervention
Group II: Control GroupActive Control1 Intervention
No additional steps in management are required for the control arm of the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Losartan
2003
Completed Phase 4
~3000

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,409 Previous Clinical Trials
855,815 Total Patients Enrolled
Joshua Rozell, MDPrincipal InvestigatorNYU Langone Health
1 Previous Clinical Trials

Media Library

Losartan (Angiotensin Receptor Blocker) Clinical Trial Eligibility Overview. Trial Name: NCT05157464 — Phase 4
Arthrofibrosis Research Study Groups: Losartan Group, Control Group
Arthrofibrosis Clinical Trial 2023: Losartan Highlights & Side Effects. Trial Name: NCT05157464 — Phase 4
Losartan (Angiotensin Receptor Blocker) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05157464 — Phase 4
~0 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top